Ultragenyx Pharmaceutical Inc (RARE)

60.01
2.50 4.30
NASDAQ : Health Care
Prev Close 57.55
Open 57.54
Day Low/High 56.75 / 61.04
52 Wk Low/High 46.52 / 135.43
Volume 442.31K
Avg Volume 590.40K
Exchange NASDAQ
Shares Outstanding 42.31M
Market Cap 2.43B
EPS -4.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Ultragenyx Reports First Quarter 2017 Financial Results And Corporate Update

Ultragenyx Reports First Quarter 2017 Financial Results And Corporate Update

Additional Phase 3 data on burosumab shows increased healing of fractures in adult XLH

Biotech Movers: Ultragenyx Jumps on Phase Three Burosumab Data

Biotech Movers: Ultragenyx Jumps on Phase Three Burosumab Data

Ultragenyx, together with Kyowa Hakko Kirin and Kyowa Kirin International, on Tuesday unveiled 24-week data from a phase three study of burosumab in adults.

Notable Friday Option Activity: RARE, EVC, W

Notable Friday Option Activity: RARE, EVC, W

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Ultragenyx Pharmaceutical Inc , where a total volume of 4,232 contracts has been traded thus far today, a contract volume which is representative of approximately 423,200 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 64% of RARE's average daily trading volume over the past month, of 661,320 shares.

Ultragenyx And Kyowa Kirin International Announce Positive Data From Pediatric Phase 2 Studies Of Burosumab (KRN23) In X-Linked Hypophosphatemia

Ultragenyx And Kyowa Kirin International Announce Positive Data From Pediatric Phase 2 Studies Of Burosumab (KRN23) In X-Linked Hypophosphatemia

Sustained reduction in bone disease and improvement in growth through 64 weeks of treatment and sustained effect on bone mineral metabolites in patients under 5 years old

Biotech Premarket Movers: Insys, Ultragenyx, Alexion

Biotech Premarket Movers: Insys, Ultragenyx, Alexion

Insys Therapeutics, Ultragenyx Pharmaceutical and Alexion Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.

Ultragenyx Announces Topline Data From Phase 2 UX007 Glucose Transporter Type-1 Deficiency Syndrome Seizure Study

Ultragenyx Announces Topline Data From Phase 2 UX007 Glucose Transporter Type-1 Deficiency Syndrome Seizure Study

Overall seizures not significantly reduced; decrease in absence seizures observed

Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios

Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios

Pharma stocks have bounced back from their prior selloff, but whether they will continue their upward trend under a Donald Trump administration remains unclear.

Ultragenyx Reports Positive Interim Data From Phase 2 Study Of KRN23 For The Treatment Of Tumor-Induced Osteomalacia

Ultragenyx Reports Positive Interim Data From Phase 2 Study Of KRN23 For The Treatment Of Tumor-Induced Osteomalacia

Company to host conference call at 11am ET Monday, September 19 to discuss results